KR102417455B1 - 심혈관 질환에서의 리라글루티드 - Google Patents

심혈관 질환에서의 리라글루티드 Download PDF

Info

Publication number
KR102417455B1
KR102417455B1 KR1020187026962A KR20187026962A KR102417455B1 KR 102417455 B1 KR102417455 B1 KR 102417455B1 KR 1020187026962 A KR1020187026962 A KR 1020187026962A KR 20187026962 A KR20187026962 A KR 20187026962A KR 102417455 B1 KR102417455 B1 KR 102417455B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
liraglutide
placebo
subject
mace
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187026962A
Other languages
English (en)
Korean (ko)
Other versions
KR20180114168A (ko
Inventor
쇠렌 라스무센
카이사 크비스트
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59723004&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102417455(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20180114168A publication Critical patent/KR20180114168A/ko
Application granted granted Critical
Publication of KR102417455B1 publication Critical patent/KR102417455B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020187026962A 2016-03-04 2017-03-03 심혈관 질환에서의 리라글루티드 Active KR102417455B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP16158739 2016-03-04
EP16158739.9 2016-03-04
EP16173917.2 2016-06-10
EP16173917 2016-06-10
EP16001329.8 2016-06-13
EP16001329 2016-06-13
US15/401,651 US9968659B2 (en) 2016-03-04 2017-01-09 Liraglutide in cardiovascular conditions
US15/401,651 2017-01-09
PCT/EP2017/054990 WO2017149112A1 (en) 2016-03-04 2017-03-03 Liraglutide in cardiovascular conditions

Publications (2)

Publication Number Publication Date
KR20180114168A KR20180114168A (ko) 2018-10-17
KR102417455B1 true KR102417455B1 (ko) 2022-07-06

Family

ID=59723004

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187026962A Active KR102417455B1 (ko) 2016-03-04 2017-03-03 심혈관 질환에서의 리라글루티드

Country Status (24)

Country Link
US (2) US9968659B2 (enExample)
EP (1) EP3423082B1 (enExample)
JP (1) JP6940512B2 (enExample)
KR (1) KR102417455B1 (enExample)
CN (2) CN108778317A (enExample)
AU (2) AU2017225841A1 (enExample)
BR (1) BR112018067344A2 (enExample)
CA (1) CA3013532C (enExample)
CL (1) CL2018002515A1 (enExample)
DK (1) DK3423082T5 (enExample)
ES (1) ES2893755T3 (enExample)
HR (1) HRP20211492T1 (enExample)
HU (1) HUE055844T2 (enExample)
IL (1) IL261169B (enExample)
MA (1) MA43704A (enExample)
MX (1) MX394179B (enExample)
MY (1) MY195657A (enExample)
PH (1) PH12018501844B1 (enExample)
PL (1) PL3423082T3 (enExample)
RS (1) RS62501B1 (enExample)
RU (1) RU2745604C2 (enExample)
SI (1) SI3423082T1 (enExample)
WO (1) WO2017149112A1 (enExample)
ZA (1) ZA201805538B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
CN118987224A (zh) * 2020-12-16 2024-11-22 香港中文大学 一种治疗受试者的衰老相关脑功能障碍的组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220255A1 (en) * 2002-04-04 2003-11-27 Knudsen Liselotte Bjerre GLP-1 agonist and cardiovascular complications

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808203A (en) 1997-05-12 1998-09-15 Medrad, Inc. Fluid pressure measurement devices
CN104826116A (zh) * 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
CN112618700A (zh) * 2004-11-12 2021-04-09 诺和诺德公司 促胰岛素肽的稳定制剂
WO2009030738A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
KR20110135411A (ko) 2009-03-27 2011-12-16 브리스톨-마이어스 스큅 컴퍼니 Ｄｐｐ-ｉｖ 억제제로 주요 유해 심장혈관 이벤트를 예방하는 방법
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US20130172244A1 (en) 2011-12-29 2013-07-04 Thomas Klein Subcutaneous therapeutic use of dpp-4 inhibitor
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
EP4151218A1 (en) 2012-05-14 2023-03-22 Boehringer Ingelheim International GmbH Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis
JP6374862B2 (ja) 2012-05-24 2018-08-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫性糖尿病、特に、ｌａｄａの治療に使用するためのｄｐｐ−４阻害剤としてのキサンチン誘導体
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
JP2016510795A (ja) 2013-03-15 2016-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用
JP6507154B2 (ja) 2013-06-14 2019-04-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及びその合併症を治療するためのｄｄｐ−４阻害薬
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
US9968659B2 (en) 2016-03-04 2018-05-15 Novo Nordisk A/S Liraglutide in cardiovascular conditions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220255A1 (en) * 2002-04-04 2003-11-27 Knudsen Liselotte Bjerre GLP-1 agonist and cardiovascular complications

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DIABETES & VASCULAR DISEASE RESEARCH APR 2012, (201204), vol. 9, no. 2, ISSN 1752-8984, pages 95 - 108*
DIABETES, US, (20090401), vol. 58, no. 4, doi:10.2337/db08-1193, ISSN 0012-1797, pages 975 - 983*
EUROPEAN JOURNAL OF NEUROLOGY, RAPID SCIENCE PUBLISHERS, GB, (20140501), vol. 21, no. Suppl.1, ISSN 1351-5101, page 154*
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, US, (20150201), vol. 100, no. 2, doi:10.1210/jc.2014-2291, ISSN 0021-972X, pages 603 - 606*
ZHONGGUO XINYAO YU LINCHUANG ZAZHI, (201106), vol. 30, no. 6, ISSN 1007-7669, pages 422 - 427*
빅토자펜주6밀리그램/밀리리터(리라글루티드)(허가일: 2010-10-06)*

Also Published As

Publication number Publication date
JP6940512B2 (ja) 2021-09-29
CA3013532A1 (en) 2017-09-08
ES2893755T3 (es) 2022-02-10
MX394179B (es) 2025-03-24
CN108778317A (zh) 2018-11-09
PH12018501844B1 (en) 2023-03-17
DK3423082T3 (da) 2021-10-11
AU2024201937A1 (en) 2024-04-11
EP3423082B1 (en) 2021-08-04
IL261169A (en) 2018-10-31
CN116327897A (zh) 2023-06-27
DK3423082T5 (da) 2023-02-06
CL2018002515A1 (es) 2018-11-09
WO2017149112A1 (en) 2017-09-08
US20180236038A1 (en) 2018-08-23
PH12018501844A1 (en) 2019-05-15
HRP20211492T1 (hr) 2021-12-24
MX2018010097A (es) 2018-11-09
US20170252408A1 (en) 2017-09-07
PL3423082T3 (pl) 2021-12-27
US9968659B2 (en) 2018-05-15
RU2018134061A3 (enExample) 2020-07-15
RU2018134061A (ru) 2020-04-06
MY195657A (en) 2023-02-03
IL261169B (en) 2019-11-28
JP2019507174A (ja) 2019-03-14
AU2017225841A1 (en) 2018-08-23
HUE055844T2 (hu) 2021-12-28
CA3013532C (en) 2019-07-23
EP3423082A1 (en) 2019-01-09
ZA201805538B (en) 2020-05-27
MA43704A (fr) 2021-04-14
BR112018067344A2 (pt) 2019-01-08
KR20180114168A (ko) 2018-10-17
SI3423082T1 (sl) 2021-10-29
RS62501B1 (sr) 2021-11-30
RU2745604C2 (ru) 2021-03-29

Similar Documents

Publication Publication Date Title
US20250262281A1 (en) Semaglutide in Cardiovascular Conditions
US12233114B2 (en) Method for treating diabetes
AU2024201937A1 (en) Liraglutide in cardiovascular conditions
US11673933B2 (en) Method for using insulin degludec for the improvement of glycemic control and reduction of acute and long-term diabetes complications
US20190091295A1 (en) Liraglutide in Renal Conditions
US20190070266A1 (en) Liraglutide in Diabetic Foot Ulcer
HK1259166A1 (en) Liraglutide in cardiovascular conditions
HK1259166B (en) Liraglutide in cardiovascular conditions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180918

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200227

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210701

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220409

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220701

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220704

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250630

Start annual number: 4

End annual number: 4